Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

BackgroundTransmission blocking vaccines targeting the sexual-stages of the malaria parasite could play a major role to achieve elimination and eradication of malaria. The Plasmodium falciparum Pfs25 protein (Pfs25) is the most clinically advanced candidate sexual-stage antigen. IMX313, a complement...

全面介紹

書目詳細資料

Principais autores:	Hans de Graaf, Ruth O. Payne, Iona Taylor, Kazutoyo Miura, Carol A. Long, Sean C. Elias, Marija Zaric, Angela M. Minassian, Sarah E. Silk, Lee Li, Ian D. Poulton, Megan Baker, Simon J. Draper, Diane Gbesemete, Nathan J. Brendish, Filipa Martins, Arianna Marini, David Mekhaiel, Nick J. Edwards, Rachel Roberts, Johan Vekemans, Sarah Moyle, Saul N. Faust, Eleanor Berrie, Alison M. Lawrie, Fergal Hill, Adrian V. S. Hill, Sumi Biswas
格式:	Artigo
語言:	Inglês
出版:	Frontiers Media S.A. 2021-07-01
叢編:	Frontiers in Immunology
主題:	Pfs25 malaria transmission-blocking IMX313 vaccine
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.694759/full
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!